+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

High-dose statin before percutaneous coronary intervention lowers risk of periprocedural myocardial infarction and 3-day major cardiac adverse events



High-dose statin before percutaneous coronary intervention lowers risk of periprocedural myocardial infarction and 3-day major cardiac adverse events



Evidence-Based Medicine 17(1): 13-14



In the current era, periprocedural myocardial infarction (MI) can still occur in a significant proportion of percutaneous coronary interventions (PCIs).1 Large periprocedural ischaemic events are associated with harm; however, even small increases in cardiac enzymes have been associated with increased long-term mortality.2 Attempts to enhance the safety of PCI have typically occurred through the use of potent antiplatelet agents (eg, aspirin, ADP receptor blockers (clopidogrel and prasugrel) and glycoprotein inhibitors (abciximab and eptifibatide)), as well as antithrombin agents (eg, unfractionated heparin, low-molecular weight heparin and bivalirudin). Although antiplatelet and antithrombin agents are effective at reducing ischaemic events, a cost from their use is sometimes paid in terms of major bleeding. Like periprocedural MI, bleeding is independently associated with increased mortality.3 Thus, drugs or devices that can reduce ischaemic events without increasing bleeding episodes or other important safety outcomes would have an.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 036320424

Download citation: RISBibTeXText


Related references

Effect of preprocedural statin use on procedural myocardial infarction and major cardiac adverse events in percutaneous coronary intervention: a meta-analysis. Journal of Invasive Cardiology 20(6): 292-295, 2008

High-dose statin pretreatment decreases periprocedural myocardial infarction and cardiovascular events in patients undergoing elective percutaneous coronary intervention: a meta-analysis of twenty-four randomized controlled trials. Plos One 9(12): E113352, 2015

Effect of High-Dose Statin Pretreatment on the Incidence of Periprocedural Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention: Grading the Evidence Through a Cumulative Meta-analysis. Clinical Cardiology 38(11): 668-678, 2016

Decreased TSP-1 following percutaneous coronary intervention is associated with major adverse cardiac events in ST-elevation myocardial infarction. Clinical Hemorheology and Microcirculation 54(1): 59-73, 2014

Serum apelin level predicts the major adverse cardiac events in patients with ST elevation myocardial infarction receiving percutaneous coronary intervention. Medicine 94(4): E449, 2015

Predictive factors of major adverse cardiac events in acute myocardial infarction patients complicated by cardiogenic shock undergoing primary percutaneous coronary intervention. Circulation Journal 69(2): 154-158, 2005

Statin administration before percutaneous coronary intervention: Impact on periprocedural myocardial infarction. Acc Current Journal Review 14(2): 45-0, 2005

Statin loading before percutaneous coronary intervention to reduce periprocedural myocardial infarction. Cardiology in Review 20(6): 319-324, 2013

Statin administration before percutaneous coronary intervention: impact on periprocedural myocardial infarction. European Heart Journal 25(20): 1822-1828, 2004

Percutaneous coronary intervention for acute coronary syndromes: no difference in 30-day efficacy or safety of high- and low-dose aspirin; double-dose clopidogrel reduces 30-day risk of cardiovascular death, myocardial infarction or stroke compared with standard dose but increases risk of major bleeding. Evidence-Based Medicine 16(3): 80-81, 2011

Short- and long-term major adverse cardiac events in patients undergoing percutaneous coronary intervention with stenting for acute myocardial infarction complicated by cardiogenic shock. Cardiology 121(1): 47-55, 2012

Soluble urokinase plasminogen activator receptor in one-year prediction of major adverse cardiac events in patients after first myocardial infarction treated with primary percutaneous coronary intervention. Archives of Medical Science 15(1): 72-77, 2019

Meta-analysis of the role of high-dose statins administered prior to percutaneous coronary intervention in reducing major adverse cardiac events in patients with coronary artery disease. Clinical and Experimental Pharmacology and Physiology 37(4): 496-500, 2010

Comparison of the Predictive Roles of Risk Scores of In-Hospital Major Adverse Cardiovascular Events in Patients with Non-ST Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention. Medical Principles and Practice 27(5): 459-465, 2018

Can a high reloading dose of atorvastatin prior to percutaneous coronary intervention reduce periprocedural myocardial infarction?. Current Medical Research and Opinion 30(3): 381-386, 2014